Federal Court of Australia [2024]: Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 4), [2024] FCA 678,
Australia
Back This judgment is a part of the following collection(s): 2025 WIPO Intellectual Property Judges ForumDate of JudgmentJune 18, 2024Issuing AuthorityFederal Court of AustraliaLevel of the Issuing AuthorityFirst InstanceType of ProcedureJudicial (Civil)Subject MatterPatents (Inventions)Plaintiff/AppellantPfizer Ireland PharmaceuticalsDefendant/RespondentSamsung Bioepis AU Pty Ltd (No. 4)Keywords
Patents,
Discovery,
Whether “fishing”,
Excessive prior art permutations under the Patents Act,
Relevance of inventor’s notes to inventive step,
Best method under the Patents Act
Judgment/DecisionEnglishFederal Court of Australia [2024]: Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 4), [2024] FCA 678 HTMLAdditional DocumentsEnglish 2025 WIPO IP Judges Forum Informal Case Summary-Federal Court of Australia [2024]: Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd (No 4), [2024] FCA 678 HTMLRelevant Legislation